Yes, primary bone cancer is rare. It accounts for just 0.2% of all new cancer diagnoses in the United States, with an estimated 3,770 new cases expected in 2025. Under U.S. law, any disease affecting fewer than 200,000 people qualifies as a rare disease, and primary bone cancer falls well below that threshold.
That rarity, however, comes with a catch: because bone cancer is so uncommon, it’s often not the first thing doctors suspect when symptoms appear. Understanding what primary bone cancer actually is, who it affects, and why it’s frequently confused with far more common conditions can help you make sense of what you’re reading or experiencing.
Primary vs. Metastatic Bone Cancer
There’s an important distinction most people miss when searching for bone cancer. Primary bone cancer, the type that originates in bone cells, is the rare one. Metastatic bone cancer, where a tumor from another organ (breast, prostate, lung) spreads to the bones, is far more common in adults. The American Cancer Society notes that cancers spreading to bone outnumber cancers starting in bone by a wide margin. When someone over 50 is told they have “bone cancer,” it’s usually metastatic disease from a cancer elsewhere in the body, not a primary bone tumor.
Primary bone cancer is what the rest of this article focuses on, since that’s the truly rare diagnosis.
The Three Most Common Types
Even within the small world of primary bone cancer, not all types behave the same way or affect the same people.
Osteosarcoma is the most common, making up about 36% of all primary bone cancers. It peaks between ages 10 and 30, which makes it one of the cancers most associated with adolescence and young adulthood. It typically develops in areas of rapid bone growth, like the knee or upper arm.
Chondrosarcoma accounts for 20 to 25% of cases and tends to strike later in life, usually between ages 30 and 60. It grows in cartilage cells and most often affects the pelvis and lower limbs. Its annual incidence is roughly 1 in every 1,000,000 people.
Ewing sarcoma represents about 16% of primary bone cancers and is primarily a disease of children and teenagers, accounting for nearly 3% of all childhood cancers. It occurs at a rate of about 2.5 to 3 cases per million per year.
Why It Matters More in Children
Malignant bone tumors make up roughly 3% of all cancers in children and adolescents. That percentage is small in absolute terms, but it’s significantly higher than the 0.2% share bone cancer holds among all adult cancers. Osteosarcoma and Ewing sarcoma together account for the vast majority of pediatric bone cancers.
This age pattern matters because persistent bone pain or swelling in a teenager is often dismissed as growing pains or a sports injury. In most cases, that’s exactly what it is. But the overlap in symptoms is one reason primary bone cancer can take a long time to diagnose, especially in young patients whose complaints seem easily explained.
Diagnosis Is Often Delayed
Because primary bone cancer is so uncommon, and because its early symptoms (deep bone pain, swelling, occasional limping) mimic dozens of more ordinary problems, there’s frequently a significant gap between the first symptom and a confirmed diagnosis. A 2025 systematic review in the journal Cancers found that the average diagnostic delay for bone sarcomas ranged from 7 weeks to 28 months, depending on the study and tumor type.
That range is strikingly wide, and it reflects a real challenge. A general practitioner who sees thousands of patients may never encounter a single case of primary bone cancer in an entire career. Pain that doesn’t improve with rest, worsens at night, or produces a noticeable lump is the pattern that typically triggers further imaging and, eventually, referral to a specialist. The key signal is bone pain that persists or worsens over weeks without a clear cause.
Known Risk Factors
Most people who develop primary bone cancer have no identifiable risk factor. But a few conditions do increase the odds.
- Inherited genetic syndromes: Li-Fraumeni syndrome, hereditary retinoblastoma, and Rothmund-Thomson syndrome all carry elevated risk for osteosarcoma. These syndromes involve mutations in tumor-suppressing genes that normally keep cell growth in check.
- Previous radiation therapy: People who received radiation treatment for another cancer, particularly during childhood, have a higher risk of developing primary bone cancer later in life.
- Certain benign bone conditions: Paget disease of the bone, a disorder of bone metabolism most common in older adults, can rarely progress to osteosarcoma. Benign cartilage growths called enchondromas and osteochondromas also carry a small risk of becoming chondrosarcoma over time.
For the vast majority of patients, though, there’s no preventable cause. Primary bone cancer appears to arise from a combination of genetic bad luck and, in some cases, periods of rapid bone growth during adolescence.
How Rare Compares to Outcomes
Rarity doesn’t automatically mean a poor prognosis, but it does create challenges. Fewer cases mean fewer specialists with deep experience, fewer clinical trials, and less public awareness. Treatment for primary bone cancer typically involves a combination of surgery and, depending on the type, chemotherapy. Outcomes vary significantly by the specific subtype and how far the cancer has spread at the time of diagnosis.
Localized osteosarcoma and Ewing sarcoma caught before they spread carry considerably better survival rates than cases diagnosed after the cancer has reached the lungs or other bones. This is one reason the diagnostic delays described above are so consequential. Chondrosarcoma, by contrast, tends to be slower growing but responds poorly to chemotherapy, making complete surgical removal the most important factor in outcomes.
Primary bone cancer’s rarity is both reassuring and frustrating. It means the vast majority of bone pain has a benign explanation. But it also means that when primary bone cancer does occur, it can take longer than it should to identify, and finding a treatment center with real expertise may require traveling to a specialized sarcoma center rather than relying on a local oncology practice.